
As you start your treatment, you may have questions about endometrial cancer, your treatment plan, and IMFINZI + chemotherapy.* To help learn the answers to some of these questions, check out the frequently asked questions below. Remember, your doctor is the best resource for answering specific questions about your treatment.
*Carboplatin and paclitaxel.
Endometrial cancer (EC) is a type of cancer that starts in the inner lining of the uterus, called the "endometrium." When EC is advanced (Stage III or IV), the cancer has spread outside the uterus to sites such as the lymph nodes, pelvis, vagina, bladder, or liver. When it is recurrent, it means that EC that was treated before has now returned.
A biomarker is a measurable sign of normal or abnormal processes, conditions, or diseases. Mismatch repair (MMR) status is an important biomarker of endometrial cancer. An MMR status test is a type of biomarker test that screens for MMR deficiency. Your doctor will order this biomarker test so that, together, you can determine an appropriate treatment plan based on your MMR status. Knowing your MMR status is important because deficient MMR (dMMR) cancers may be treated with a type of medicine called "immunotherapy."
IMFINZI is a type of immunotherapy treatment used with chemotherapy* to treat advanced or recurrent endometrial cancer that is deficient mismatch repair (dMMR). IMFINZI may cause the immune system to attack healthy cells.
*Carboplatin and paclitaxel.
An immunotherapy is a type of cancer treatment that works with the immune system to find and attack cancer; immunotherapies may also attack healthy cells.
Chemotherapy* attacks all fast-growing cells, including cancer cells. Immunotherapy works with the immune system to find and attack cancer. IMFINZI and chemotherapy* may also affect healthy cells.
*Carboplatin and paclitaxel.
IMFINZI is an intravenous (IV) infusion given at your doctor’s office or an infusion center. If your doctor prescribes IMFINZI in combination with chemotherapy* to treat your advanced or recurrent dMMR endometrial cancer, you will be given this combination for 6 cycles of your treatment before receiving IMFINZI alone. For these cycles during which you receive IMFINZI and chemotherapy*, you will receive IMFINZI first followed by chemotherapy* on the same day.
*Carboplatin and paclitaxel.
The number of treatments will be determined by your doctor, depending on the condition of your cancer. You will stop receiving IMFINZI if your cancer progresses or if side effects become intolerable.
While on IMFINZI, you may experience side effects. This is because IMFINZI can cause your immune system to attack normal organs and tissues and can affect the way they work. These problems can sometimes become serious or life-threatening and can lead to death.
Tell your doctor if you have any side effect that bothers you or that does not go away.
These are not all of the possible side effects of IMFINZI. Ask your healthcare provider or pharmacist for more information.
*Carboplatin and paclitaxel.
IMFINZI is a medicine that may treat certain cancers by working with your immune system. IMFINZI can cause your immune system to attack normal organs and tissues in any area of your body and can affect the way they work. These problems can sometimes become severe or life-threatening and can lead to death. You can have more than one of these problems at the same time. These problems may happen anytime during treatment or even after your treatment has ended.
IMFINZI is a prescription medicine that is used in combination with the chemotherapy medicines carboplatin and paclitaxel followed by IMFINZI alone to treat a type of uterine cancer called endometrial cancer that has spread (advanced) or has come back (recurred) and a laboratory test shows that your tumor is mismatch repair deficient (dMMR).
It is not known if IMFINZI is safe and effective in children.
Getting medical treatment right away may help keep these problems from becoming more serious. Your healthcare provider will check you for these problems during your treatment with IMFINZI. Your healthcare provider may treat you with corticosteroid or hormone replacement medicines. Your healthcare provider may also need to delay or completely stop treatment with IMFINZI if you have severe side effects.
Before you receive IMFINZI, tell your healthcare provider about all of your medical conditions, including if you:
Females who are able to become pregnant:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
The most common side effects of IMFINZI when used with platinum-containing chemotherapy in adults with endometrial cancer include inflammation of the nerves causing numbness, weakness, tingling or burning pain of the arms and legs, muscle or bone pain, nausea, hair loss, feeling tired, stomach (abdominal) pain, constipation, rash, decreased level of magnesium in the blood, increased liver function tests, diarrhea, vomiting, cough, decreased level of potassium in the blood, shortness of breath, headache, increased level of alkaline phosphate in the blood, and decreased appetite.
Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of IMFINZI. Ask your healthcare provider or pharmacist for more information.
Call your doctor for medical advice about side effects. You may report side effects related to AstraZeneca products. If you prefer to
report these to the FDA, either visit www.FDA.gov/medwatch or call 1-800-FDA-1088.
Call your doctor for medical advice about side effects. You may report side effects related to AstraZeneca products. If you prefer to
report these to the FDA, either visit www.FDA.gov/medwatch or call 1-800-FDA-1088.
IMFINZI is a prescription medicine that is used in combination with the chemotherapy medicines carboplatin and paclitaxel followed by IMFINZI alone to treat a type of uterine cancer called endometrial cancer that has spread (advanced) or has come back (recurred) and a laboratory test shows that your tumor is mismatch repair deficient (dMMR).
It is not known if IMFINZI is safe and effective in children.
Please see Full Prescribing Information including Medication Guide for IMFINZI.
IMFINZI is a medicine that may treat certain cancers by working with your immune system. IMFINZI can cause your immune system to attack normal organs and tissues in any area of your body and can affect...
IMFINZI is a medicine that may treat...
IMFINZI is a prescription medicine that is used in combination with the chemotherapy medicines carboplatin and paclitaxel followed by IMFINZI alone to treat a type of uterine cancer called endometrial cancer that has...
IMFINZI is a medicine that may treat certain cancers by work...
IMFINZI is a medicine that may treat certain cancers by working with your immune system. IMFINZI can cause your immune system to...